JP2013520424A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013520424A5 JP2013520424A5 JP2012553967A JP2012553967A JP2013520424A5 JP 2013520424 A5 JP2013520424 A5 JP 2013520424A5 JP 2012553967 A JP2012553967 A JP 2012553967A JP 2012553967 A JP2012553967 A JP 2012553967A JP 2013520424 A5 JP2013520424 A5 JP 2013520424A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- powder
- ray diffraction
- substantially similar
- crystal form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 COc1cccc(F)c1C(c1c-2ccc(Cl)c1)=NCc1c-2nc(Nc2ccc(C([O-])=*)c(OC)c2)nc1 Chemical compound COc1cccc(F)c1C(c1c-2ccc(Cl)c1)=NCc1c-2nc(Nc2ccc(C([O-])=*)c(OC)c2)nc1 0.000 description 1
- ZLHFILGSQDJULK-UHFFFAOYSA-M COc1cccc(F)c1C(c1c-2ccc(Cl)c1)=NCc1c-2nc(Nc2ccc(C([O-])=O)c(OC)c2)nc1 Chemical compound COc1cccc(F)c1C(c1c-2ccc(Cl)c1)=NCc1c-2nc(Nc2ccc(C([O-])=O)c(OC)c2)nc1 ZLHFILGSQDJULK-UHFFFAOYSA-M 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30604710P | 2010-02-19 | 2010-02-19 | |
| US61/306,047 | 2010-02-19 | ||
| PCT/US2011/024883 WO2011103089A1 (en) | 2010-02-19 | 2011-02-15 | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6--methoxyphenyl)-5h -pyrimido[5,4-d][2]benzazepin-2yl]amino}-2-methoxybenzoate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015117195A Division JP2015180679A (ja) | 2010-02-19 | 2015-06-10 | ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013520424A JP2013520424A (ja) | 2013-06-06 |
| JP2013520424A5 true JP2013520424A5 (cg-RX-API-DMAC10.html) | 2014-03-27 |
Family
ID=44483264
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012553967A Withdrawn JP2013520424A (ja) | 2010-02-19 | 2011-02-15 | ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形 |
| JP2015117195A Pending JP2015180679A (ja) | 2010-02-19 | 2015-06-10 | ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015117195A Pending JP2015180679A (ja) | 2010-02-19 | 2015-06-10 | ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8653064B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2536279A4 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2013520424A (cg-RX-API-DMAC10.html) |
| CN (2) | CN102770024A (cg-RX-API-DMAC10.html) |
| BR (1) | BR112012020557A8 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2788774A1 (cg-RX-API-DMAC10.html) |
| RU (1) | RU2012140021A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2011103089A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2747326C (en) | 2008-12-22 | 2017-05-16 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd20 antibodies |
| JO3434B1 (ar) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| BR112012020557A8 (pt) | 2010-02-19 | 2018-01-02 | Millennium Pharm Inc | formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio |
| AR086656A1 (es) | 2011-06-03 | 2014-01-15 | Millennium Pharm Inc | Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a |
| US20130303519A1 (en) * | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
| CN103724350A (zh) * | 2012-10-11 | 2014-04-16 | 韩冰 | 一类治疗脑性瘫痪的化合物及其用途 |
| CA2907726A1 (en) | 2013-03-22 | 2014-09-25 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc1/2 inhibitors and selective inhibitors of aurora a kinase |
| CN103408552B (zh) * | 2013-07-25 | 2015-07-01 | 苏州明锐医药科技有限公司 | 阿立塞替的制备方法 |
| CN103408551B (zh) * | 2013-07-25 | 2015-08-05 | 苏州明锐医药科技有限公司 | 阿立塞替的制备方法 |
| US10335494B2 (en) | 2013-12-06 | 2019-07-02 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-CD30 antibodies |
| US20180207173A1 (en) | 2015-07-21 | 2018-07-26 | Millennium Pharmaceuticals, Inc. | Administration of aurora kinase inhibitor and chemotherapeutic agents |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025075211A1 (en) | 2023-10-03 | 2025-04-10 | Takeda Pharmaceutical Company Limited | Alisertib and paclitaxel for treating small cell lung cancer |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025245045A1 (en) | 2024-05-21 | 2025-11-27 | The Regents Of The University Of California | Methods of treating lung cancer |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4099012A (en) | 1975-08-28 | 1978-07-04 | Ciba-Geigy Corporation | 2-pyrazolyl-benzophenones |
| US4481142A (en) | 1979-02-07 | 1984-11-06 | Hoffmann-La Roche Inc. | Pyrimido-2-benzazepines |
| IL59316A (en) | 1979-02-07 | 1983-07-31 | Sparamedica Ag | Phenylpyrimidobenzazepine derivatives,their preparation and pharmaceutical compositions containing them |
| US4469633A (en) | 1980-05-16 | 1984-09-04 | Hoffmann-La Roche Inc. | N-oxides of 5-oxo-1-phenyl-2-benzazepines |
| EP0273697A3 (en) | 1986-12-30 | 1989-11-29 | Merck & Co. Inc. | 2-benzazepines with 5- and 6- membered heterocyclic rings |
| US5166151A (en) | 1988-03-25 | 1992-11-24 | Merck & Co., Inc. | 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof |
| US5210082A (en) | 1991-05-16 | 1993-05-11 | Merck & Co., Inc. | 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders |
| US5747487A (en) | 1993-07-29 | 1998-05-05 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| IL126095A0 (en) | 1996-03-08 | 1999-05-09 | Zeneca Ltd | Azolobenzazepine derivatives as neurogically active agents |
| US6057329A (en) | 1996-12-23 | 2000-05-02 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives |
| GB9713087D0 (en) | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
| AU744636B2 (en) | 1997-09-29 | 2002-02-28 | Meiji Seika Pharma Co., Ltd. | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic |
| US6277844B1 (en) | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
| WO2000067754A1 (en) | 1999-05-12 | 2000-11-16 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
| WO2001010462A1 (en) | 1999-08-11 | 2001-02-15 | Idec Pharmaceuticals Corporation | Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies |
| MXPA03005609A (es) | 2000-12-21 | 2003-10-06 | Vertex Pharma | Compuestos de pirazol utiles como inhibidores de la proteina cinasa. |
| US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
| US7238685B2 (en) | 2001-08-09 | 2007-07-03 | Actelion Pharmaceuticals Ltd. | Benzo-fused heterocycles as endothelin antagonists |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| NZ551370A (en) | 2004-05-14 | 2009-08-28 | Millennium Pharm Inc | Compounds and methods for inhibiting mitotic progression by inhibiting of aurora kinase |
| SI1905773T1 (sl) * | 2004-05-14 | 2013-01-31 | Millennium Pharmaceuticals, Inc. | Spojine in postopki za inhibiranje mitotične progresije z inhibiranjem aurora kinaze |
| KR20070086188A (ko) | 2004-11-17 | 2007-08-27 | 미카나 테라퓨틱스, 인크. | 키나제 억제제 |
| JP2008526723A (ja) | 2004-12-30 | 2008-07-24 | アステックス、セラピューティックス、リミテッド | Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体 |
| US20070104785A1 (en) | 2005-07-29 | 2007-05-10 | Navale Suryakant V | Tablets of linezolid form iii and processes for their preparation |
| DK1962830T3 (da) | 2005-12-23 | 2013-06-24 | Glaxosmithkline Llc | Azaindolhæmmere af aurorakinaser. |
| US20080004286A1 (en) | 2006-06-30 | 2008-01-03 | Schering Corporation | Method of Using Substituted Piperidines that Increase P53 Activity |
| EP2054413A2 (en) | 2006-08-09 | 2009-05-06 | Millennium Pharmaceuticals, Inc. | Pyridobenzazepine compounds and methods for inhibiting mitotic progression |
| CL2007003244A1 (es) * | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| US20090203671A1 (en) | 2007-11-27 | 2009-08-13 | Abbott Laboratories | Method of treating cancer |
| CA2747326C (en) | 2008-12-22 | 2017-05-16 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-cd20 antibodies |
| JO3635B1 (ar) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| JO3434B1 (ar) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| BR112012020557A8 (pt) | 2010-02-19 | 2018-01-02 | Millennium Pharm Inc | formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio |
-
2011
- 2011-02-15 BR BR112012020557A patent/BR112012020557A8/pt not_active Application Discontinuation
- 2011-02-15 CA CA2788774A patent/CA2788774A1/en not_active Abandoned
- 2011-02-15 JP JP2012553967A patent/JP2013520424A/ja not_active Withdrawn
- 2011-02-15 CN CN2011800099967A patent/CN102770024A/zh active Pending
- 2011-02-15 WO PCT/US2011/024883 patent/WO2011103089A1/en not_active Ceased
- 2011-02-15 RU RU2012140021/04A patent/RU2012140021A/ru not_active Application Discontinuation
- 2011-02-15 US US13/027,523 patent/US8653064B2/en active Active
- 2011-02-15 CN CN201410055631.3A patent/CN104031049A/zh active Pending
- 2011-02-15 EP EP11745114.6A patent/EP2536279A4/en not_active Withdrawn
-
2014
- 2014-01-09 US US14/151,524 patent/US20140357622A1/en not_active Abandoned
-
2015
- 2015-06-10 JP JP2015117195A patent/JP2015180679A/ja active Pending
-
2016
- 2016-10-13 US US15/292,363 patent/US10017513B2/en active Active